The effect of formulary restrictions on patient and payer outcomes: A systematic literature review

Journal of Managed Care and Specialty Pharmacy

Volumn 23, Issue 8, 2017, Pages 893-901

  Park, Yujin ^a   Raza, Syed ^b   George, Aneesh ^b   Agrawal, Rumjhum ^b   Ko, John ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS HEALTHCARE PVT LTD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL OUTCOME; COCHRANE LIBRARY; COST CONTROL; DRUG CONTROL; DRUG COST; DRUG INFORMATION; DRUG UTILIZATION; ECONOMIC EVALUATION; EMBASE; FORMULARY RESTRICTION; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MEDICATION COMPLIANCE; MEDLINE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PATIENT-REPORTED OUTCOME; PHARMACOECONOMICS; PHARMACY; RESOURCE MANAGEMENT; REVIEW; SYSTEMATIC REVIEW; CALIFORNIA; COST BENEFIT ANALYSIS; ECONOMICS; PATIENT ATTITUDE; PROCEDURES; REIMBURSEMENT; TREATMENT OUTCOME;

DRUG;

CALIFORNIA; COST-BENEFIT ANALYSIS; DRUG UTILIZATION; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MEDICATION ADHERENCE; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT SATISFACTION; PHARMACEUTICAL PREPARATIONS; PHARMACEUTICAL SERVICES; PHARMACY; TREATMENT OUTCOME;

EID: 85025630214     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2017.23.8.893     Document Type: Review

References (82)

1. Centers for Medicare & Medicaid Services. National health expenditures 2015 highlights. Available at: https://www. cms. gov/Research-Statistics-Dataand-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/highlights. pdf. Accessed June 28, 2017
2. Buff MJ, Terrell TD. The role of third-party payers in medical cost increases. J Am Phys Surg. 2014;19(2):75-79
3. Centers for Disease Control and Prevention. Table 95. Personal health care expenditures, by source of funds and type of expenditure: United States, selected years 1960-2014. In: National Center for Health Statistics. Health, United States, 2015: with special feature on racial and ethnic health disparities. 2016. Available at: http://www. cdc. gov/nchs/data/hus/2015/095. pdf. Accessed June 14, 2017
4. Kongsvedt P. Essentials of Managed Health Care. 6th ed. Sudbury, MA: Jones and Bartlett Publishers; 2013
5. Ridic G, Gleason S, Ridic O. Comparisons of health care systems in the United States, Germany and Canada. Mater Sociomed. 2012;24(2):112-20
6. Carlton RI, Bramley TJ, Nightengale B, Conner TM, Zacker C. Review of outcomes associated with formulary restrictions: focus on step therapy. Am J Pharm Benefits. 2010;2(1):50-58
7. McRae J, Vogenberg FR, Beaty SW, Mearns E, Varga S, Pizzi L. A review of U. S. drug costs relevant to Medicare, Medicaid, and commercial insurers post-Affordable Care Act enactment, 2010-2016. Pharmacoeconomics. 2017;35(2):215-23
8. Blue Cross Blue Shield Blue Care Network of Michigan. Why do I need prior authorization for a prescription drug? Available at: http://www. bcbsm. com/index/health-insurance-help/faqs/plan-types/pharmacy/why-do-i-needprior-authorization-for-prescription-drug. html. Accessed June 14, 2017
9. Blue Cross Blue Shield Blue Care Network of Michigan. What's step therapy and how does it work? Available at: http://www. bcbsm. com/medicare/help/understanding-plans/pharmacy-prescription-drugs/step-therapy. html. Accessed June 14, 2017
10. Starner CI, Fenrick B, Coleman J, Wickersham P, Gleason PP. Rosiglitazone prior authorization safety policy: a cohort study. J Manag Care Pharm. 2012;18(3):225-33. Available at: http://www. jmcp. org/doi/abs/10. 18553/jmcp. 2012. 18. 3. 225
11. Bazalo G, Weiss RC, Joshi AV. Impact of a prior authorization for pregabalin on health plan drug expenditures. Am J Manag Care. 2010;16 (5 Suppl):S154-59
12. Huang X, Liu Z, Shankar RR, Rajpathak S. Description of anti-diabetic drug utilization pre-and post-formulary restriction of sitagliptin: findings from a national health plan. Curr Med Res Opin. 2015;31(8):1495-500
13. Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care. 2005;11(10):621-28
14. Gibson T, Ozminkowski R, Goetzel R. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11(11):730-40
15. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69
16. Lu C, Ross-Degnan D, Soumerai S, Pearson S. Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature-2001-2007. BMC Health Serv Res. 2008;8:75
17. Shoemaker S, Pozniak A, Subramanian R, Mauch D. Effect of 6 managed care pharmacy tools: a review of the literature. J Manag Care Pharm. 2010;16(6 Suppl A):S3-20. Available at: http://www. jmcp. org/doi/abs/10. 18553/jmcp. 2010. 16. S6-A. 1
18. Motheral BR. Pharmaceutical step-therapy interventions: a critical review of the literature. J Manag Care Pharm. 2011;17(2):143-55. Available at: http://www. jmcp. org/doi/abs/10. 18553/jmcp. 2011. 17. 2. 143
19. Mark TL, Gibson TM, McGuigan K, Chu BC. The effects of antidepressant step therapy protocols on pharmaceutical and medical utilization and expenditures. Am J Psychiatry. 2010;167(10):1202-09
20. Williams SA, Buysman EK, Hulbert EM, Bergeson JG, Zhang B, Graham J. Hemoglobin A1c outcomes and health care resource use in type 2 diabetes mellitus patients treated with combination oral antidiabetic drugs through step therapy and loose-dose and fixed-dose combinations. Manag Care. 2012;21(7):40-48
21. Mark TL, Gibson TB, McGuigan KA. The effects of antihypertensive step-therapy protocols on pharmaceutical and medical utilization and expenditures. Am J Manag Care. 2009;15(2):123-31
22. Starner CI, McClelland RS, Qiu Y, Zabinski RA, Cotter N, Gleason PP. A linezolid prior authorization program: clinical and economic outcomes. Am J Pharm Benefits. 2014;6(2):81-88
23. Johnston SS, Sadosky A, Cappelleri JC, et al. Pregabalin prior authorization and potential medication-medication and medication-condition interactions. Am J Pharm Benefits. 2014;6(6):e185-92
24. Clark RE, Baxter JD, Barton BA, Aweh G, O'Connell E, Fisher WH. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence. Health Serv Res. 2014;49(6):1964-79
25. Labiner DM, Drake KW. Formularies, costs, and quality of care: formulary restrictions are not the answer, especially for epilepsy. Neurol Clin Pract. 2013;3(1):71-74
26. Happe LE, Clark D, Holliday E, Young T. A systematic literature review assessing the directional impact of managed care formulary restrictions on medication adherence, clinical outcomes, economic outcomes, and health care resource utilization. J Manag Care Spec Pharm. 2014;20(7):677-84. Available at: http://www. jmcp. org/doi/abs/10. 18553/jmcp. 2014. 20. 7. 677
27. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Version 5. 1. 0. March 2011. Available at: http://handbook. cochrane. org/. Accessed June 14, 2017
28. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. The Ottawa Hospital Research Institute. Available at: http://www. ohri. ca/programs/clinical_epidemiology/oxford. asp. Accessed June 14, 2017
29. Cochrane Effective Practice and Organisation of Care. EPOC resources for review authors. 2017. Available at: epoc. cochrane. org/epoc-resourcesreview-authors. Accessed June 28, 2017
30. Critical Appraisal Skills Programme (CASP). 10 questions to help you make sense of qualitative research. Qualitative Research Checklist 31. 05. 13. Available at: http://media. wix. com/ugd/dded87_29c5b002d99342f788c6ac6 70e49f274. pdf. Accessed June 14, 2017
31. Accurso AJ. The effect of a payer-mandated decrease in buprenorphine dose on relapse rates of patients with opioid dependence, a natural experiment. Presented at: SGIM 38th Annual Meeting; April 22-25, 2015; Toronto, ON, Canada. Available at: https://higherlogicdownload. s3. amazonaws. com/SGIM/d307f134-78da-4fb8-beae-def2a3c048e5/UploadedImages/AM15%20 docs/Oral%20Presentations/Abstract%20Session%20I4. pdf. Accessed June 14, 2017
32. Blomquist J. Generic first strategy in PPI class drives lowest net cost. J Manag Care Pharm. 2010;16(7):533 [Abstract]. Available at: http://www. jmcp. org/doi/pdf/10. 18553/jmcp. 2010. 16. issue-7
33. Bergeson JG, Worley K, Louder A, Ward M, Graham J. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare advantage prescription drug plan population. J Manag Care Pharm. 2013;19(5):374-84. Available at: http://www. jmcp. org/doi/10. 18553/jmcp. 2013. 19. 5. 374
34. Brown JD, Barrett A, Caffery E, Hourihan K, Ireys HT. Medication continuity among Medicaid beneficiaries with schizophrenia and bipolar disorder. Psychiatr Serv. 2013;64(9):878-85
35. Delate T, Mager DE, Sheth J, Motheral BR. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am J Manag Care. 2005;11(1):29-36
36. Ben-Joseph R, Chen CC, De AP, Wade RL, Shah D. Consequences of patient access restrictions to branded oxycodone hydrochloride extendedrelease tablets on healthcare utilization and costs in U. S. health plans. J Med Econ. 2014;17(10):708-18
37. Adams AS, Zhang F, LeCates RF, et al. Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees. Arch Intern Med. 2009;169(8):750-56
38. Carroll NV, Smith JC, Berringer RA, Oestreich GL. Evaluation of an automated system for prior authorization: a COX-2 inhibitor example. Am J Manag Care. 2006;12(9):501-08
39. Gleason PP, Williams C, Hrdy S, Hartwig SC, Lassen D. Medical and pharmacy expenditures after implementation of a cyclooxygenase-2 inhibitor prior authorization program. Pharmacotherapy. 2005;25(7):924-34
40. Devine JW, Trice S, Allerman AA, Bacon TA. The effect of a prior authorization program for proton-pump inhibitors on medication persistence among the elderly. Value Health. 2009;12(3):A60 [Abstract PGI12]. Available at: http://www. valueinhealthjournal. com/article/S1098-3015(10)73359-3/abstract. Accessed June 14, 2017
41. Cotter ND. Promoting the ADA's diabetes type 2 treatment guidelines through pharmacy step-therapy programs. J Manag Care Pharm. 2011;17(7):568 [Abstract]. Available at: http://www. jmcp. org/doi/pdf/10. 18553/jmcp. 2011. 17. issue-7
42. Farley JF, Cline RR, Schommer JC, Hadsall RS, Nyman JA. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications. Clin Ther. 2008;30(8):1524-39
43. Erdman DR, LeBlanc L, Christiansen B, Gregory RS. Aromatase inhibitors utilization management opportunities: assessment of patient diagnoses, cost savings, and controlling off-label use. J Manag Care Pharm. 2010;16(2):142 [Abstract]. Available at: http://www. jmcp. org/doi/pdf/10. 18553/jmcp. 2010. 16. issue-2
44. Dunn JD, Cannon E, Mitchell MP, Curtiss FR. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system. J Manag Care Pharm. 2006;12(4):294-302. Available at: http://www. jmcp. org/doi/abs/10. 18553/jmcp. 2006. 12. 4. 294
45. Harman M, Vogenberg FR. Employer perspectives on a specialty drug step-therapy program evaluation. Am Health Drug Benefits. 2016;9(6):319-21
46. Hartung DM, Ketchum KL, Haxby DG. An evaluation of Oregon's evidence-based practitioner-managed prescription drug plan. Health Aff (Millwood). 2006;25(5):1423-32
47. Goldman D, Fastenau J, Dirani R, et al. Medicaid prior authorization policies and imprisonment among patients with schizophrenia. Am J Manag Care. 2014;20(7):577-86
48. Garcia MM, Angelini MC, Thomas T, Lenz K, Jeffrey P. Implementation of an opioid management initiative by a state Medicaid program. J Manag Care Spec Pharm. 2014;20(5):447-54. Available at: http://www. jmcp. org/doi/10. 18553/jmcp. 2014. 20. 5. 447
49. Gleason PP, Phillips J, Fenrick BA, Delgado-Riley A, Starner CI. Dalfampridine prior authorization program: a cohort study. J Manag Care Pharm. 2013;19(1):18-25. Available at: http://www. jmcp. org/doi/abs/10. 18553/jmcp. 2013. 19. 1. 18
50. Hatoum HT, Lin S-J, Balu S. Impact of 5-hydroxytryptamine-3 receptor antagonist step therapy on severe chemotherapy-induced nausea and vomiting events in patients with lymphoma. Blood. 2011;118(21):3137 [Abstract 3137]. Available at: http://www. bloodjournal. org/content/118/21/3137?ssochecked= true. Accessed June 14, 2017
51. Keast SL, Thompson D, Farmer K, Smith M, Nesser N, Harrison D. Impact of a prior authorization policy for montelukast on clinical outcomes for asthma and allergic rhinitis among children and adolescents in a state Medicaid program. J Manag Care Spec Pharm. 2014;20(6):612-21. Available at: http://www. jmcp. org/doi/abs/10. 18553/jmcp. 2014. 20. 6. 612
52. Herink M, Ketchum K, Tobias A, Carroll M. Evaluation of the oral anticoagulant prior authorization policy in the Oregon Medicaid program. Presented at: American College of Clinical Pharmacy Global Conference on Clinical Pharmacy; October 17-21, 2015; San Francisco, CA
53. Johnston SS, Udall M, Alvir J, et al. Association between pregabalin access restrictions and pain-related health care utilization and expenditures in Medicare supplemental health plans. J Manag Care Pharm. 2012;18(7):542 [Abstract]. Available at: http://www. jmcp. org/doi/pdf/10. 18553/jmcp. 2012. 18. issue-7
54. Lu CY, Adams AS, Ross-Degnan D, et al. Association between prior authorization for medications and health service use by Medicaid patients with bipolar disorder. Psychiatr Serv. 2011;62(2):186-93
55. Lu CY, Law MR, Soumerai SB, et al. Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study. Clin Ther. 2011;33(1):135-44
56. LaPensee K, Carson R, Werner P, et al. Effect of equivalent and nonequivalent substitution of prescribed drugs for depression and anxiety disorders on patients' treatment adherence and perception. Value Health. 2010;13(3):A118 [Abstract PMH75]. Available at: http://www. valueinhealthjournal. com/article/S1098-3015(10)72570-5/abstract. Accessed June 14, 2017
57. Louder AM, Joshi AV, Ball AT, Cappelleri JC, Deminski MC, Sanchez RJ. Impact of celecoxib restrictions in Medicare beneficiaries with arthritis. Am J Manag Care. 2011;17(7):503-12
58. Lin SJ, Hatoum HT, Buchner D, Cox D, Balu S. Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study. BMC Health Serv Res. 2012;12:215
59. Law MR, Lu CY, Soumerai SB, et al. Impact of two Medicaid priorauthorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study. Clin Ther. 2010;32(4):729-41
60. Shen X, Stuart B, Powers C, Tom S, Magder L, Perfetto EM. How do formulary restrictions affect medication use and costs for low-income subsidy recipients in Medicare part d plans? Value Health. 2016;19(3):A261 [Abstract PHP17]. Available at: http://www. valueinhealthjournal. com/article/S1098-3015(16)00863-9/abstract. Accessed June 14, 2017
61. Margolis JM, Johnston SS, Chu BC, et al. Effects of a Medicaid prior authorization policy for pregabalin. Am J Manag Care. 2009;15(10):e95-102
62. Margolis JM, Cao Z, Onukwugha E, et al. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. Am J Manag Care. 2010;16(6):447-56
63. Risser JA, Vash PD, Nieto L. Does prior authorization of sibutramine improve medication compliance or weight loss? Obes Res. 2005;13(1):86-92
64. Null KD, Moll K, Sadosky A, Pasquale MK, Cappelleri JC, Parsons B. Trends associated with implementing and lifting a pregabalin step therapy policy. Am J Pharm Benefits. 2016;8(2):e17-24
65. Nau DP, Chi C, Mallya U, Kirking DM. Member satisfaction related to self-reported cost share and difficulty in obtaining prescription drugs in a university pharmacy benefit plan. J Manag Care Pharm. 2007;13(2):135-41. Available at: http://www. jmcp. org/doi/abs/10. 18553/jmcp. 2007. 13. 2. 135
66. Placzek HE, Masters ET, Gu T, et al. Prior authorization in the treatment of patients with pDPN and FM. Pain Pract. 2015;15(1):E9-19
67. Seabury S, Lakdawalla DN, Walter D, et al. Medicaid formulary restrictions and expenditures for patients with major depressive disorder. Value Health. 2014;17(3):A222 [Abstract PMH78]. Available at: http://www. valueinhealthjournal. com/article/S1098-3015(14)01348-5/abstract. Accessed June 14, 2017
68. Suehs BT, Louder A, Udall M, Cappelleri JC, Joshi AV, Patel NC. Impact of a pregabalin step therapy policy among Medicare advantage beneficiaries. Pain Pract. 2014;14(5):419-26
69. Simeone JC, Marcoux RM, Quilliam BJ. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid program. J Manag Care Pharm. 2010;16(5):317-28. Available at: http://www. jmcp. org/doi/abs/10. 18553/jmcp. 2010. 16. 5. 317
70. Siracuse MV, Vuchetich PJ. Impact of Medicaid prior authorization requirement for COX-2 inhibitor drugs in Nebraska. Health Serv Res. 2008;43(1 Pt 2):435-50
71. Soumerai SB, Zhang F, Ross-Degnan D, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff (Millwood). 2008;27(3):w185-95
72. Suehs BT, Sikirica V, Mudumby P, Dufour R, Patel NC. Impact of a step therapy for guanfacine extended-release on medication utilization and health care expenditures among individuals receiving treatment for ADHD. J Manag Care Spec Pharm. 2015;21(9):793-802, 802a-i. Available at: http://www. jmcp. org/doi/10. 18553/jmcp. 2015. 21. 9. 793
73. Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health. 2006;9(2):77-89
74. Sun SX, Jing Y, Aruru M, Lee KY. Economic evaluation of a prior authorization program for biologic response modifiers. Drug Benefit Trends. 2008;20:26-31
75. Sun SX, Jing Y, Lee KY, McMurray J, Young E. Impact of formulary management and step therapy for non-sedating antihistamines on prescription drug utilisation and costs. J Med Econ. 2007;10(4):367-78
76. West JC, Wilk JE, Rae DS, et al. First-year Medicare part D prescription drug benefits: medication access and continuity among dual eligible psychiatric patients. J Clin Psychiatry. 2010;71(4):400-10
77. Yokoyama K, Yang W, Preblick R, Frech-Tamas F. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy. J Manag Care Pharm. 2007;13(3):235-44. Available at: http://www. jmcp. org/doi/abs/10. 18553/jmcp. 2007. 13. 3. 235
78. Zhang Y, Adams AS, Ross-Degnan D, Zhang F, Soumerai SB. Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder. Psychiatr Serv. 2009;60(4):520-57
79. Walthour A, Seymour L, Tackett R, Perri M. Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents. Ann Pharmacother. 2010;44(5):809-18
80. Udall M, Louder A, Suehs BT, Cappelleri JC, Joshi AV, Patel NC. Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population. J Med Econ. 2013;16(6):784-92
81. Zhang Z, Jannsen X, Rogers N, Shetty S, Etemad L. Impact of generic step therapy of divalproex ER, levetiracetam, lamotrigine, and topiramate on health care utilization in epilepsy patients. J Manag Care Pharm. 2012;18(2):183 [Abstract]. Available at: http://www. jmcp. org/doi/pdf/10. 18553/jmcp. 2012. 18. issue-2
82. Whiteley J, Landsman-Blumberg PB, Cao Z, Alvir J, Harnett J. Effects of a desvenlafaxine prior authorization on health care resource utilization and costs in commercially insured patients. J Manag Care Pharm. 2011;17(7):557 [Abstract]. Available at: http://www. jmcp. org/doi/pdf/10. 18553/jmcp. 2011. 17. issue-7